Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Published byΑδελφά Παχής Modified over 5 years ago

Similar presentations

Presentation on theme: "Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)"— Presentation transcript:

1 Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes.
Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A) Day 12 B16.F10-OVA tumor volumes (left) and animal survival (right) of mice with varying Batf3 genotypes after necroptotic fibroblast injections. n = 4 to 12 mice per group. d.11, day 11. (B) B16.F10-OVA tumor growth (left) and animal survival (right) upon coadministration of necroptotic fibroblasts with depleting antibodies against either CD4+ or CD8+ leukocytes. n = 6 to 11 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < Black arrows indicate intratumoral dying cell injections. Error bars represent SEM. Data are pooled from two to four independent experiments. Annelise G. Snyder et al. Sci. Immunol. 2019;4:eaaw2004 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Download ppt "Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)"

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Fibroblast activation in WT and NFATc2-deficient mice.

Fibroblast activation in WT and NFATc2-deficient mice.
MP cells are generated from naïve cells in the periphery.

MP cells are generated from naïve cells in the periphery.
LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.
Cytotoxicity of MSP samples to normal and cancer cell lines.

Cytotoxicity of MSP samples to normal and cancer cell lines.
Specific depletion of TFH and LCMV-specific CD4 T cells.

Specific depletion of TFH and LCMV-specific CD4 T cells.
VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.

VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.
CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Three different types of transfer functions with a codomain of [0,1].

Three different types of transfer functions with a codomain of [0,1].
Regulatory CD4+ T cell–derived IL-10 is important for B cell differentiation and the GC response. Regulatory CD4+ T cell–derived IL-10 is important for.

Regulatory CD4+ T cell–derived IL-10 is important for B cell differentiation and the GC response. Regulatory CD4+ T cell–derived IL-10 is important for.
LV activation of DCs and subsequent CD8+ T cell priming are dependent on STING and cGAS but not on MyD88, TRIF, or MAVS. LV activation of DCs and subsequent.

LV activation of DCs and subsequent CD8+ T cell priming are dependent on STING and cGAS but not on MyD88, TRIF, or MAVS. LV activation of DCs and subsequent.
Human PBMC-derived MERS-CoV–specific T cells are multifunctional.

Human PBMC-derived MERS-CoV–specific T cells are multifunctional.
Virus-specific T cell responses are detected in all MERS survivors.

Virus-specific T cell responses are detected in all MERS survivors.
Platelets are required for hFcγRIIA-induced anaphylaxis.

Platelets are required for hFcγRIIA-induced anaphylaxis.
β-Glucans do not modulate epithelial IL-33 or AHR.

β-Glucans do not modulate epithelial IL-33 or AHR.
Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.
Tfr cell–derived IL-10 is important for B cell differentiation and the GC response. Tfr cell–derived IL-10 is important for B cell differentiation and.

Tfr cell–derived IL-10 is important for B cell differentiation and the GC response. Tfr cell–derived IL-10 is important for B cell differentiation and.

Similar presentations

Ads by Google